{"hands_on_practices": [{"introduction": "Effective palliative decision-making begins with an honest and accurate appraisal of prognosis. This practice introduces the use of a quantitative tool, the Palliative Prognostic Score (PaP), to structure this assessment [@problem_id:4675920]. By systematically combining key clinical variables into a single score, clinicians can move beyond subjective impressions to a data-driven estimate of short-term survival, providing a crucial foundation for discussions about the appropriateness of invasive surgical interventions versus a focus on non-operative, comfort-oriented care.", "problem": "A general surgery service is considering whether to perform an invasive decompressive procedure for malignant large-bowel obstruction in a patient with disseminated colorectal cancer, versus pursuing non-operative measures and Hospice referral. To structure decision-making at end of life, the team plans to use the Palliative Prognostic Score (PaP). The PaP is an additive point score derived from multivariable logistic regression in palliative oncology cohorts, where each clinical variable contributes a fixed weight to a linear predictor that stratifies the predicted probability of survival at $30$ days. The following variables and point weights are established at your institution based on prior validation studies:\n\n- Dyspnea: present adds $2.0$ points; absent adds $0$ points.\n- Anorexia: present adds $1.5$ points; absent adds $0$ points.\n- Karnofsky Performance Status (KPS), expressed as a fraction from $0$ to $1$ (with $1$ representing $100\\%$), contributes:\n  - $0.70$ to $1.00$: $0$ points,\n  - $0.50$ to $0.60$: $1.5$ points,\n  - $0.30$ to $0.40$: $2.5$ points,\n  - $0.10$ to $0.20$: $4.0$ points.\n- Clinical Prediction of Survival (CPS) in weeks contributes:\n  - $>12$ weeks: $0$ points,\n  - $7$ to $11$ weeks: $2.0$ points,\n  - $3$ to $6$ weeks: $3.5$ points,\n  - $\\le 2$ weeks: $5.5$ points.\n- White Blood Cell (WBC) count in $\\times 10^{9}\\!/\\text{L}$ contributes:\n  - $\\le 8.5$: $0$ points,\n  - $8.6$ to $11.0$: $1.0$ points,\n  - $>11.0$: $2.5$ points.\n- Lymphocyte fraction (absolute lymphocyte count divided by total WBC) contributes:\n  - $\\ge 0.20$: $0$ points,\n  - $0.12$ to $0.199$: $0.8$ points,\n  - $0.12$: $2.0$ points.\n\nPaP risk groups for $30$-day survival are defined by the total score:\n- Group A: PaP $\\le 5.5$,\n- Group B: PaP $5.6$ to $11.0$,\n- Group C: PaP $>11.0$.\n\nA $68$-year-old patient presents with malignant obstruction and the following clinical profile prior to decision-making:\n- Dyspnea due to a symptomatic malignant pleural effusion (present),\n- Anorexia (present),\n- KPS (fraction) of $0.40$,\n- CPS by the most experienced attending surgeon is $\\le 2$ weeks,\n- WBC count of $12.4 \\times 10^{9}\\!/\\text{L}$,\n- Lymphocyte fraction of $0.08$.\n\nStarting from the principle that validated additive clinical risk scores represent the linear component of a logistic regression model for short-term survival, compute the PaP score by summing the appropriate point contributions from the variables above. Interpret the resulting PaP category in terms of predicted $30$-day survival and remark briefly on how such categorization should inform whether to pursue invasive surgical palliation versus non-operative measures. Express the final PaP score as a dimensionless number and round your answer to three significant figures.", "solution": "The problem is valid as it is scientifically grounded in established clinical prognostic scoring systems, is well-posed with all necessary data provided, and is framed in objective, verifiable terms. The task is to calculate a Palliative Prognostic Score (PaP) for a given patient and interpret its implications for clinical decision-making.\n\nThe Palliative Prognostic Score (PaP) is an additive score, which we can denote as $S_{\\text{PaP}}$. It is a linear combination of weighted clinical variables. The total score is the sum of the points contributed by each variable:\n$$S_{\\text{PaP}} = S_{\\text{dyspnea}} + S_{\\text{anorexia}} + S_{\\text{KPS}} + S_{\\text{CPS}} + S_{\\text{WBC}} + S_{\\text{lymph}}$$\nwhere each term $S_i$ represents the point value for a specific clinical variable $i$. We will now determine the value for each term based on the patient's clinical profile.\n\nThe patient is a $68$-year-old with disseminated colorectal cancer. The clinical data are as follows:\n- Dyspnea is present.\n- Anorexia is present.\n- Karnofsky Performance Status (KPS) is $0.40$.\n- Clinical Prediction of Survival (CPS) is $\\le 2$ weeks.\n- White Blood Cell (WBC) count is $12.4 \\times 10^{9}\\!/\\text{L}$.\n- Lymphocyte fraction is $0.08$.\n\nWe will now assign points for each variable according to the scoring system provided.\n\n1.  **Dyspnea:** The patient has dyspnea. According to the rules, the presence of dyspnea contributes $2.0$ points.\n    $$S_{\\text{dyspnea}} = 2.0$$\n\n2.  **Anorexia:** The patient has anorexia. The presence of anorexia contributes $1.5$ points.\n    $$S_{\\text{anorexia}} = 1.5$$\n\n3.  **Karnofsky Performance Status (KPS):** The patient's KPS is $0.40$. This value falls into the category \"$0.30$ to $0.40$,\" which contributes $2.5$ points.\n    $$S_{\\text{KPS}} = 2.5$$\n\n4.  **Clinical Prediction of Survival (CPS):** The attending surgeon's CPS is $\\le 2$ weeks. This prognosis corresponds to a contribution of $5.5$ points.\n    $$S_{\\text{CPS}} = 5.5$$\n\n5.  **White Blood Cell (WBC) Count:** The patient's WBC count is $12.4 \\times 10^{9}\\!/\\text{L}$. This value is greater than $11.0 \\times 10^{9}\\!/\\text{L}$ ($12.4 > 11.0$). This corresponds to a contribution of $2.5$ points.\n    $$S_{\\text{WBC}} = 2.5$$\n\n6.  **Lymphocyte Fraction:** The patient's lymphocyte fraction is $0.08$. This value is less than $0.12$ ($0.08  0.12$). This corresponds to a contribution of $2.0$ points.\n    $$S_{\\text{lymph}} = 2.0$$\n\nNow, we sum these point contributions to calculate the total PaP score, $S_{\\text{PaP}}$:\n$$S_{\\text{PaP}} = 2.0 + 1.5 + 2.5 + 5.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 3.5 + 2.5 + 5.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 6.0 + 5.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 11.5 + 2.5 + 2.0$$\n$$S_{\\text{PaP}} = 14.0 + 2.0$$\n$$S_{\\text{PaP}} = 16.0$$\n\nThe total PaP score for this patient is $16.0$. The problem requests this value rounded to three significant figures, which $16.0$ already satisfies.\n\nNext, we interpret this score by classifying the patient into a risk group. The defined groups are:\n- Group A: PaP $\\le 5.5$\n- Group B: PaP $5.6$ to $11.0$\n- Group C: PaP $> 11.0$\n\nSince the calculated score is $S_{\\text{PaP}} = 16.0$, which is greater than $11.0$, the patient falls into **Group C**.\n\nFinally, we remark on the implications for clinical decision-making. The problem states that the PaP score stratifies the predicted probability of survival at $30$ days. Group C represents the cohort with the highest scores and, consequently, the lowest predicted probability of $30$-day survival. In the context of deciding between invasive surgical palliation (e.g., decompressive colectomy) and non-operative measures (e.g., symptom management and Hospice care), a very poor prognosis as indicated by a Group C PaP score is a critical factor. The principle of proportionality suggests that the significant physiological stress, morbidity, potential for complications, and recovery time of a major invasive procedure are likely to outweigh the potential benefits of palliating the obstruction in a patient whose expected survival is extremely short. Therefore, a high PaP score strongly supports a recommendation against aggressive surgical intervention and in favor of a focus on quality of life, symptom control, and end-of-life care planning with Hospice services. The score provides an objective, data-driven foundation for this difficult and sensitive clinical discussion.", "answer": "$$\\boxed{16.0}$$", "id": "4675920"}, {"introduction": "Beyond determining prognosis, excellence in palliative care hinges on meticulous symptom management, particularly the control of pain. This exercise provides hands-on practice in opioid rotation, a core competency for managing patients with evolving analgesic needs, especially during transitions of care like discharge to home hospice [@problem_id:4675896]. Mastering equianalgesic dosing calculations is essential for ensuring patient comfort is maintained safely and effectively, accounting for crucial pharmacological principles like incomplete cross-tolerance.", "problem": "A patient with advanced malignant bowel obstruction under palliative care is being transitioned from inpatient intravenous (IV) opioid therapy to an oral regimen in preparation for home hospice. Over the last $24$ hours, the patient received a continuous infusion of intravenous morphine at $2.5 \\, \\text{mg/hour}$ and additional Patient-Controlled Analgesia (PCA) boluses totaling $18 \\, \\text{mg}$. The plan is to rotate to oral oxycodone and design a schedule that maintains analgesia while mitigating risk at discharge.\n\nUse the following well-tested facts from equianalgesic dosing and rotation principles:\n- $10 \\, \\text{mg}$ intravenous morphine is approximately equivalent to $30 \\, \\text{mg}$ oral morphine.\n- $30 \\, \\text{mg}$ oral morphine is approximately equivalent to $20 \\, \\text{mg}$ oral oxycodone.\n- To account for incomplete cross-tolerance when switching opioids, reduce the calculated equianalgesic daily dose of the new opioid by $33\\%$.\n- For safety at discharge, schedule $85\\%$ of the reduced daily oxycodone dose evenly every $4$ hours, reserving the remaining $15\\%$ for breakthrough dosing.\n\nDerive from first principles the scheduled oral oxycodone dose per administration every $4$ hours. Express the final answer in $\\text{mg}$ and round your answer to two significant figures.", "solution": "The problem is valid as it is scientifically grounded in established principles of clinical pharmacology, well-posed, objective, and contains all necessary information to derive a unique solution.\n\nThe primary objective is to calculate the scheduled oral oxycodone dose, administered every $4$ hours, for a patient transitioning from intravenous (IV) morphine. The derivation proceeds in a sequence of logical steps, starting from the current total daily dose of IV morphine.\n\nStep 1: Calculate the Total Daily Dose (TDD) of IV Morphine.\nThe patient's total consumption of IV morphine over the last $24$ hours is the sum of the dose from the continuous infusion and the dose from Patient-Controlled Analgesia (PCA) boluses.\n\nLet $D_{\\text{IV-M,total}}$ be the total daily dose of IV morphine.\nThe dose from the continuous infusion is the rate multiplied by the duration:\n$$D_{\\text{infusion}} = 2.5 \\, \\text{mg/hour} \\times 24 \\, \\text{hours} = 60 \\, \\text{mg}$$\nThe dose from PCA boluses is given as:\n$$D_{\\text{PCA}} = 18 \\, \\text{mg}$$\nThe TDD of IV morphine is the sum of these two amounts:\n$$D_{\\text{IV-M,total}} = D_{\\text{infusion}} + D_{\\text{PCA}} = 60 \\, \\text{mg} + 18 \\, \\text{mg} = 78 \\, \\text{mg}$$\n\nStep 2: Convert the TDD of IV Morphine to the Equianalgesic TDD of Oral Morphine.\nThe problem provides the conversion factor: $10$ mg of IV morphine is equivalent to $30$ mg of oral morphine. The conversion ratio from IV to oral morphine is therefore:\n$$C_{\\text{IV-M} \\to \\text{O-M}} = \\frac{30 \\, \\text{mg oral morphine}}{10 \\, \\text{mg IV morphine}} = 3$$\nLet $D_{\\text{O-M,total}}$ be the equianalgesic TDD of oral morphine.\n$$D_{\\text{O-M,total}} = D_{\\text{IV-M,total}} \\times C_{\\text{IV-M} \\to \\text{O-M}} = 78 \\, \\text{mg} \\times 3 = 234 \\, \\text{mg}$$\n\nStep 3: Convert the TDD of Oral Morphine to the Equianalgesic TDD of Oral Oxycodone.\nThe problem provides the conversion factor: $30$ mg of oral morphine is equivalent to $20$ mg of oral oxycodone. The conversion ratio from oral morphine to oral oxycodone is:\n$$C_{\\text{O-M} \\to \\text{O-Oxy}} = \\frac{20 \\, \\text{mg oral oxycodone}}{30 \\, \\text{mg oral morphine}} = \\frac{2}{3}$$\nLet $D_{\\text{O-Oxy,initial}}$ be the initial calculated equianalgesic TDD of oral oxycodone.\n$$D_{\\text{O-Oxy,initial}} = D_{\\text{O-M,total}} \\times C_{\\text{O-M} \\to \\text{O-Oxy}} = 234 \\, \\text{mg} \\times \\frac{2}{3} = 156 \\, \\text{mg}$$\n\nStep 4: Apply Dose Reduction for Incomplete Cross-Tolerance.\nTo ensure safety when rotating between opioids, the calculated dose is reduced to account for incomplete cross-tolerance. The required reduction is $33\\%$. The remaining dose fraction is $100\\% - 33\\% = 67\\%$, or $0.67$.\nLet $D_{\\text{O-Oxy,reduced}}$ be the reduced TDD of oral oxycodone.\n$$D_{\\text{O-Oxy,reduced}} = D_{\\text{O-Oxy,initial}} \\times (1 - 0.33) = 156 \\, \\text{mg} \\times 0.67 = 104.52 \\, \\text{mg}$$\n\nStep 5: Calculate the Scheduled Daily Dose of Oral Oxycodone.\nThe regimen specifies that $85\\%$ of the reduced TDD is for scheduled doses, and the remaining $15\\%$ is for breakthrough pain.\nLet $D_{\\text{O-Oxy,scheduled}}$ be the total daily scheduled dose of oral oxycodone.\n$$D_{\\text{O-Oxy,scheduled}} = D_{\\text{O-Oxy,reduced}} \\times 0.85 = 104.52 \\, \\text{mg} \\times 0.85 = 88.842 \\, \\text{mg}$$\n\nStep 6: Calculate the Scheduled Dose Per Administration.\nThe scheduled dose is administered every $4$ hours. The number of administrations in a $24$-hour period is:\n$$N_{\\text{doses}} = \\frac{24 \\, \\text{hours}}{4 \\, \\text{hours/dose}} = 6 \\, \\text{doses}$$\nLet $d_{\\text{scheduled}}$ be the dose per administration. This is the total daily scheduled dose divided by the number of doses.\n$$d_{\\text{scheduled}} = \\frac{D_{\\text{O-Oxy,scheduled}}}{N_{\\text{doses}}} = \\frac{88.842 \\, \\text{mg}}{6} = 14.807 \\, \\text{mg}$$\n\nStep 7: Round to the Required Significant Figures.\nThe problem requires the final answer to be rounded to two significant figures. The calculated value is $14.807$. The first two significant figures are $1$ and $4$. The third digit is $8$, which is greater than or equal to $5$, so we round up the second digit.\n$$d_{\\text{scheduled,rounded}} \\approx 15 \\, \\text{mg}$$\nThe scheduled oral oxycodone dose per administration every $4$ hours is $15$ mg.", "answer": "$$\\boxed{15}$$", "id": "4675896"}, {"introduction": "The most challenging decisions in surgical palliation involve weighing disparate outcomes—longer survival in a difficult health state versus shorter survival with higher quality of life. This final practice introduces a formal framework from decision analysis, expected utility theory, to navigate these trade-offs quantitatively [@problem_id:4675889]. By learning to derive patient-specific utilities and calculate Quality-Adjusted Life Weeks (QALWs), you can translate a patient's personal values into the decision-making process, ensuring that the chosen strategy aligns not just with clinical possibilities but with what matters most to the individual.", "problem": "A $78$-year-old with unresectable hypopharyngeal carcinoma, severe dysphagia, and a prognosis of approximately $12$ weeks is deliberating among three palliation strategies. You will use expected utility theory and quality adjustment to construct a utility-based decision from first principles of expected value and patient-specific utilities elicited by the time trade-off method.\n\nBase principles and definitions:\n- The time trade-off (TTO) utility for a health state is defined as $U = \\frac{t^{*}}{t}$, where $t$ is the duration in the health state and $t^{*}$ is the duration in perfect health that the patient considers equivalent to $t$ in the given state.\n- Quality-Adjusted Life Weeks (QALWs) over a time horizon are computed as the sum of products of time spent in each state multiplied by the utility of that state.\n- The expected value principle applies: the expected QALWs of a strategy is the probability-weighted sum over all possible outcome paths of the QALWs along that path.\n\nPatient-specific TTO utilities were elicited as follows for $t = 12$ weeks:\n- For “tube feeds at home,” the patient is indifferent between $12$ weeks with tube feeds at home and $9$ weeks in perfect health.\n- For “nasogastric tube in hospital,” the patient is indifferent between $12$ weeks with a nasogastric tube in hospital and $3$ weeks in perfect health.\n- For “oral intake with mild pain,” the patient is indifferent between $12$ weeks with oral intake and mild pain and $10.8$ weeks in perfect health.\n\nFrom these, define utilities:\n- $U_{\\text{TFH}}$ for “tube feeds at home,”\n- $U_{\\text{NG}}$ for “nasogastric tube in hospital,”\n- $U_{\\text{O}}$ for “oral intake with mild pain,”\nwith “death” assigned utility $0$.\n\nThree decision strategies are under consideration:\n\n- Strategy A (Percutaneous Endoscopic Gastrostomy (PEG) to home):\n  - Immediate procedure with probability of immediate death $0.03$ (utility $0$ for the entire horizon).\n  - With probability $0.97$, the patient survives the procedure and lives the remaining $12$ weeks. Conditional on survival:\n    - With probability $0.80$, the entire $12$ weeks are spent at home with tube feeds.\n    - With probability $0.20$, there is a single $1$-week readmission with a nasogastric tube in hospital at week $6$, with the remaining $11$ weeks at home with tube feeds. Assume total survival remains $12$ weeks.\n\n- Strategy B (Nasogastric (NG) tube in hospital):\n  - The patient remains hospitalized with a nasogastric tube for the entire remaining $12$ weeks. Assume no survival alteration and no additional state changes.\n\n- Strategy C (Oral intake with mild pain, at home):\n  - With probability $0.30$, an aspiration event occurs at week $4$, leading to a single $1$-week hospitalization with a nasogastric tube, after which the patient returns home to resume oral intake with mild pain for the remaining time. Total survival remains $12$ weeks. Thus, along this path, the time allocation is $4$ weeks oral at home, $1$ week nasogastric in hospital, and $7$ additional weeks oral at home.\n  - With probability $0.70$, no aspiration occurs; the entire $12$ weeks are at home with oral intake and mild pain.\n\nTasks:\n1. Using the TTO definition, compute $U_{\\text{TFH}}$, $U_{\\text{NG}}$, and $U_{\\text{O}}$.\n2. Using the expected value principle and the QALW definition, compute the expected QALWs for each strategy over the $12$-week horizon.\n3. Determine the maximum expected QALWs among the three strategies.\n\nExpress your final numerical answer in quality-adjusted life weeks (QALWs). Round your answer to four significant figures.", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, objective, and complete. All data, definitions, and conditions are explicitly provided. The framework of expected utility theory, using Quality-Adjusted Life Weeks (QALWs) and utilities derived from the time trade-off (TTO) method, is a standard and formally sound approach in medical decision analysis. The clinical scenario is plausible, and the probabilities and timelines are internally consistent. Therefore, the problem is valid and a solution can be derived.\n\nThe solution proceeds in three steps as requested by the problem statement.\n\n**1. Computation of Utilities**\n\nThe problem defines the time trade-off (TTO) utility for a health state as $U = \\frac{t^{*}}{t}$, where $t$ is the duration in the health state and $t^{*}$ is the duration in perfect health that the patient considers equivalent. The time horizon for utility elicitation is given as $t = 12$ weeks. The utility of death is defined as $0$.\n\n-   For “tube feeds at home,” the patient is indifferent between $t = 12$ weeks in this state and $t^{*} = 9$ weeks in perfect health. The utility, $U_{\\text{TFH}}$, is:\n    $$U_{\\text{TFH}} = \\frac{t^{*}}{t} = \\frac{9}{12} = 0.75$$\n\n-   For “nasogastric tube in hospital,” the patient is indifferent between $t = 12$ weeks in this state and $t^{*} = 3$ weeks in perfect health. The utility, $U_{\\text{NG}}$, is:\n    $$U_{\\text{NG}} = \\frac{t^{*}}{t} = \\frac{3}{12} = 0.25$$\n\n-   For “oral intake with mild pain,” the patient is indifferent between $t = 12$ weeks in this state and $t^{*} = 10.8$ weeks in perfect health. The utility, $U_{\\text{O}}$, is:\n    $$U_{\\text{O}} = \\frac{t^{*}}{t} = \\frac{10.8}{12} = 0.9$$\n\n**2. Computation of Expected Quality-Adjusted Life Weeks (QALWs)**\n\nThe expected QALWs for each strategy, denoted $E[Q]$, is calculated by summing the QALWs of each possible outcome path, weighted by the probability of that path. The total time horizon is $12$ weeks.\n\n-   **Strategy A (Percutaneous Endoscopic Gastrostomy (PEG))**\n    This strategy has two initial outcomes: immediate death (with probability $0.03$) or survival (with probability $0.97$).\n    -   Path of immediate death: The QALWs are $0$. The contribution to the expected value is $0.03 \\times 0 = 0$.\n    -   Path of survival: If the patient survives, there are two sub-paths.\n        -   Sub-path A1 (probability $0.80$): The patient spends $12$ weeks at home with tube feeds. The QALWs for this sub-path are $Q_{A1} = 12 \\text{ weeks} \\times U_{\\text{TFH}} = 12 \\times 0.75 = 9$.\n        -   Sub-path A2 (probability $0.20$): The patient spends $11$ weeks at home with tube feeds and $1$ week in the hospital with a nasogastric tube. The QALWs for this sub-path are $Q_{A2} = (11 \\text{ weeks} \\times U_{\\text{TFH}}) + (1 \\text{ week} \\times U_{\\text{NG}}) = (11 \\times 0.75) + (1 \\times 0.25) = 8.25 + 0.25 = 8.5$.\n    The expected QALWs for Strategy A, $E[Q_A]$, is the sum of the probability-weighted outcomes:\n    $$E[Q_A] = (0.03 \\times 0) + 0.97 \\times [(0.80 \\times Q_{A1}) + (0.20 \\times Q_{A2})]$$\n    $$E[Q_A] = 0.97 \\times [(0.80 \\times 9) + (0.20 \\times 8.5)]$$\n    $$E[Q_A] = 0.97 \\times [7.2 + 1.7] = 0.97 \\times 8.9 = 8.633$$\n\n-   **Strategy B (Nasogastric (NG) tube in hospital)**\n    This strategy is deterministic. The patient spends the entire $12$ weeks in the hospital with an NG tube. The expected QALWs, $E[Q_B]$, is:\n    $$E[Q_B] = 12 \\text{ weeks} \\times U_{\\text{NG}} = 12 \\times 0.25 = 3$$\n\n-   **Strategy C (Oral intake with mild pain)**\n    This strategy has two possible outcomes: an aspiration event (probability $0.30$) or no aspiration event (probability $0.70$).\n    -   Path C1 (aspiration, probability $0.30$): The patient spends $4$ weeks with oral intake, $1$ week with an NG tube in the hospital, and the final $7$ weeks with oral intake. This amounts to a total of $11$ weeks with oral intake and $1$ week with an NG tube. The QALWs for this path are $Q_{C1} = (11 \\text{ weeks} \\times U_{\\text{O}}) + (1 \\text{ week} \\times U_{\\text{NG}}) = (11 \\times 0.9) + (1 \\times 0.25) = 9.9 + 0.25 = 10.15$.\n    -   Path C2 (no aspiration, probability $0.70$): The patient spends the entire $12$ weeks with oral intake. The QALWs for this path are $Q_{C2} = 12 \\text{ weeks} \\times U_{\\text{O}} = 12 \\times 0.9 = 10.8$.\n    The expected QALWs for Strategy C, $E[Q_C]$, is the sum of the probability-weighted outcomes:\n    $$E[Q_C] = (0.30 \\times Q_{C1}) + (0.70 \\times Q_{C2})$$\n    $$E[Q_C] = (0.30 \\times 10.15) + (0.70 \\times 10.8)$$\n    $$E[Q_C] = 3.045 + 7.56 = 10.605$$\n\n**3. Determination of Maximum Expected QALWs**\n\nNow, we compare the expected QALWs for the three strategies:\n-   $E[Q_A] = 8.633$ QALWs\n-   $E[Q_B] = 3.0$ QALWs\n-   $E[Q_C] = 10.605$ QALWs\n\nThe maximum expected QALWs is given by $\\max(E[Q_A], E[Q_B], E[Q_C])$.\n$$\\max(8.633, 3.0, 10.605) = 10.605$$\nThe problem requires the answer to be rounded to four significant figures. The value $10.605$ rounded to four significant figures is $10.61$.\nTherefore, the maximum expected QALWs among the three strategies is $10.61$. This corresponds to Strategy C (Oral intake with mild pain).", "answer": "$$\\boxed{10.61}$$", "id": "4675889"}]}